Recent Updates
Recently added Catalysts
NTLA

Intellia Therapeutics to Present at October Healthcare Investor Conferences

Key Takeaway: CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that members of its manage
Price reaction · baseline $53.92 (2022-09-23 close) · clean, no other NTLA news in the window
day 0 close · peak
+0.5%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+76%
120-day peak, hindsight
Typical move
9.6%
average across 8 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
NTLA-2002
Phase 3 · Hereditary Angioedema

Full Press Release Details

CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that members of its management team will be presenting at the following upcoming investor conferences in October:
Chardan’s 6th Annual Genetic Medicines Conference, New York
Date: Monday, October 3, 2022
Format: Fireside chat
2022 Truist Securities Genetic Medicine Summit, New York
Genome Editing Panel
Date: Thursday, October 20, 2022
Format: Panel discussion
A live webcast of Intellia’s fireside chat at the Chardan conference will be accessible through the Events and Presentations page of the Investors & Media section of the company’s website at www.intelliatx.com. Replay of the webcast will be available on Intellia’s website for at least 30 days following the presentation.
About Intellia Therapeutics
Last updated: Sep 26, 2022